Corcept Therapeutics is a commercial-stage company engaged in the discovery and development of drugs that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the hormone cortisol. Co. has marketed Korlym (mifepristone) in the U.S. for the treatment of patients with Cushing's syndrome. Co.'s primary compounds have entered the clinic as potential treatments for serious disorders, including Cushing's syndrome, solid tumors (such as ovarian cancer, castration-resistant prostate cancer and adrenocortical cancer with cortisol excess), antipsychotic induced weight gain and non-alcoholic steatohepatitis. The CORT YTD return is shown above.
The YTD Return on the CORT YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether CORT YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CORT YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|